Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhang | - |
dc.contributor.author | Z. | - |
dc.contributor.author | Ha | - |
dc.contributor.author | S.H. | - |
dc.contributor.author | Moon | - |
dc.contributor.author | Y.J. | - |
dc.contributor.author | Hussein | - |
dc.contributor.author | U.K. | - |
dc.contributor.author | Song | - |
dc.contributor.author | Y. | - |
dc.contributor.author | Kim | - |
dc.contributor.author | K.M. | - |
dc.contributor.author | Park | - |
dc.contributor.author | S.-H. | - |
dc.contributor.author | Park, See-hyoung | - |
dc.contributor.author | H.S. | - |
dc.contributor.author | Park | - |
dc.contributor.author | B.-H. | - |
dc.contributor.author | Ahn | - |
dc.contributor.author | A.-R. | - |
dc.contributor.author | Lee | - |
dc.contributor.author | S.-A. | - |
dc.contributor.author | Ahn | - |
dc.contributor.author | S.J. | - |
dc.contributor.author | Kim | - |
dc.contributor.author | J.R. | - |
dc.contributor.author | Jang | - |
dc.contributor.author | K.Y. | - |
dc.date.available | 2021-03-17T07:48:38Z | - |
dc.date.created | 2021-02-26 | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1756-9966 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hongik/handle/2020.sw.hongik/12545 | - |
dc.description.abstract | Background: SIRT6 has diverse roles in cells, and the role of SIRT6 in tumorigenesis is controversial. Considering the role of SIRT6 as an inducer of DNA damage repair, it might be involved in resistance to anti-cancer therapy. Methods: We evaluated the prognostic significance of SIRT6 in 37 osteosarcomas and investigated the therapeutic efficacy of SIRT6 on the anticancer effects of doxorubicin, olaparib, and ATM inhibitor. Results: Immunohistochemical expression of SIRT6 was significantly associated with shorter overall survival and relapse-free survival of osteosarcoma patients, especially in patients who received adjuvant chemotherapy. In U2OS and KHOS/NP osteosarcoma cells, knock-down of SIRT6 significantly potentiated apoptotic effects of doxorubicin and SIRT6 overexpression induced resistance to doxorubicin. Moreover, SIRT6 induced the DNA damage repair pathway and SIRT6-mediated resistance to doxorubicin was attenuated by blocking the DNA damage repair pathway with olaparib and ATM inhibitor. Conclusions: This study suggests that suppression of SIRT6 in combination with doxorubicin might be an effective modality in the treatment of osteosarcoma patients, especially for osteosarcomas with shorter survival with high expression of SIRT6. © 2020, The Author(s). | - |
dc.publisher | BioMed Central Ltd | - |
dc.title | Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, See-hyoung | - |
dc.identifier.doi | 10.1186/s13046-020-01759-9 | - |
dc.identifier.scopusid | 2-s2.0-85096078253 | - |
dc.identifier.bibliographicCitation | Journal of Experimental and Clinical Cancer Research, v.39, no.1 | - |
dc.relation.isPartOf | Journal of Experimental and Clinical Cancer Research | - |
dc.citation.title | Journal of Experimental and Clinical Cancer Research | - |
dc.citation.volume | 39 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordAuthor | apoptosis | - |
dc.subject.keywordAuthor | DNA damage | - |
dc.subject.keywordAuthor | doxorubicin | - |
dc.subject.keywordAuthor | Osteosarcoma | - |
dc.subject.keywordAuthor | SIRT6 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
94, Wausan-ro, Mapo-gu, Seoul, 04066, Korea02-320-1314
COPYRIGHT 2020 HONGIK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.